Annette J. Vangsted

Brescia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.

Journal: Blood cancer journal

Published: March 23, 2026

Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers.

Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers.

Journal: British journal of haematology

Published: February 20, 2026

Progression-Free and Overall Survival After KRd Consolidation in FDG PET/CT Positive Patients After ASCT: A Phase II Study (CONPET).

Progression-Free and Overall Survival After KRd Consolidation in FDG PET/CT Positive Patients After ASCT: A Phase II Study (CONPET).

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 14, 2025

The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.

The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.

Journal: Haematologica

Published: July 10, 2025

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.

Journal: Blood

Published: June 03, 2025

Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial.

Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial.

Journal: EClinicalMedicine

Published: April 20, 2025

Cytogenetic abnormalities in multiple myeloma patients according to age: A real-world study by the Nordic Myeloma Study Group.

Cytogenetic abnormalities in multiple myeloma patients according to age: A real-world study by the Nordic Myeloma Study Group.

Journal: British journal of haematology

Published: March 19, 2025

Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group.

Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group.

Journal: Haematologica

Published: January 31, 2025

A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.

A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.

Journal: Future oncology (London, England)

Published: September 17, 2024

Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study.

Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study.

Journal: European journal of haematology

Published: August 30, 2024

Large differencies in age-specific survival in multiple myeloma in the nordic countries.

Large differencies in age-specific survival in multiple myeloma in the nordic countries.

Journal: Blood cancer journal

Published: December 20, 2023

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Journal: The New England journal of medicine

Published: December 12, 2023

Showing 1-12 of 89

Last Updated: 09/26/2026